BACKGROUND: Mdm2 is a natural inhibitor of p53 function and its overexpression impairs p53 transcriptional activity. T-->G single-nucleotide polymorphism at position 309 (SNP309) of mdm2 induces overexpression of mdm2, but inhibits p53. OBJECTIVES: To determine whether SNP309 is a risk-modifier polymorphism in colorectal cancer (CRC) and whether tumour selection of P53 mutations are influenced by SNP309. METHODS: Single-stranded conformation polymorphism and automatic sequencing were performed. RESULTS: SNP309 is not associated with the risk of CRC or recurrence of tumours. These data do not over-ride the tumour-selection capabilities of P53 mutations in CRC. However, a significant association with non-dominant-negative P53 mutations (p = 0.02) was found. CONCLUSIONS: MDM2-SNP309 favours tumour selection of non-dominant negative P53 mutations in CRC, which also show an earlier age of tumour onset.
BACKGROUND:Mdm2 is a natural inhibitor of p53 function and its overexpression impairs p53 transcriptional activity. T-->G single-nucleotide polymorphism at position 309 (SNP309) of mdm2 induces overexpression of mdm2, but inhibits p53. OBJECTIVES: To determine whether SNP309 is a risk-modifier polymorphism in colorectal cancer (CRC) and whether tumour selection of P53 mutations are influenced by SNP309. METHODS: Single-stranded conformation polymorphism and automatic sequencing were performed. RESULTS: SNP309 is not associated with the risk of CRC or recurrence of tumours. These data do not over-ride the tumour-selection capabilities of P53 mutations in CRC. However, a significant association with non-dominant-negative P53 mutations (p = 0.02) was found. CONCLUSIONS:MDM2-SNP309 favours tumour selection of non-dominant negative P53 mutations in CRC, which also show an earlier age of tumour onset.
Authors: Kaisa Sotamaa; Sandya Liyanarachchi; Jukka-Pekka Mecklin; Heikki Järvinen; Lauri A Aaltonen; Päivi Peltomäki; Albert de la Chapelle Journal: Clin Cancer Res Date: 2005-10-01 Impact factor: 12.531
Authors: P Alhopuro; S K Ylisaukko-Oja; W J Koskinen; P Bono; J Arola; H J Järvinen; J-P Mecklin; T Atula; R Kontio; A A Mäkitie; S Suominen; I Leivo; P Vahteristo; L-M Aaltonen; L A Aaltonen Journal: J Med Genet Date: 2005-09 Impact factor: 6.318
Authors: Nicoleta C Arva; Tamara R Gopen; Kathryn E Talbott; Latoya E Campbell; Agustin Chicas; David E White; Gareth L Bond; Arnold J Levine; Jill Bargonetti Journal: J Biol Chem Date: 2005-05-20 Impact factor: 5.157
Authors: Gareth L Bond; Wenwei Hu; Elisabeth E Bond; Harlan Robins; Stuart G Lutzker; Nicoleta C Arva; Jill Bargonetti; Frank Bartel; Helge Taubert; Peter Wuerl; Kenan Onel; Linwah Yip; Shih-Jen Hwang; Louise C Strong; Guillermina Lozano; Arnold J Levine Journal: Cell Date: 2004-11-24 Impact factor: 41.582
Authors: Chiara Menin; Maria Chiara Scaini; Gian Luca De Salvo; Martina Biscuola; Monica Quaggio; Giovanni Esposito; Claudio Belluco; Marco Montagna; Simona Agata; Emma D'Andrea; Donato Nitti; Alberto Amadori; Roberta Bertorelle Journal: J Natl Cancer Inst Date: 2006-02-15 Impact factor: 13.506
Authors: Elnaz F Firoz; Melanie Warycha; Jan Zakrzewski; Danuta Pollens; Guimin Wang; Richard Shapiro; Russell Berman; Anna Pavlick; Prashiela Manga; Harry Ostrer; Julide Tok Celebi; Hideko Kamino; Farbod Darvishian; Linda Rolnitzky; Judith D Goldberg; Iman Osman; David Polsky Journal: Clin Cancer Res Date: 2009-03-24 Impact factor: 12.531
Authors: Fiona E M Paulin; Mary O'Neill; Gillian McGregor; Andrew Cassidy; Alison Ashfield; Clinton W Ali; Alastair J Munro; Lee Baker; Colin A Purdie; David P Lane; Alastair M Thompson Journal: BMC Cancer Date: 2008-10-01 Impact factor: 4.430
Authors: Vanessa Cristina Jacovas; Diego Luiz Rovaris; Orlando Peréz; Soledad de Azevedo; Gabriel Souza Macedo; José Raul Sandoval; Alberto Salazar-Granara; Mercedes Villena; Jean-Michel Dugoujon; Rafael Bisso-Machado; Maria Luiza Petzl-Erler; Francisco Mauro Salzano; Patricia Ashton-Prolla; Virginia Ramallo; Maria Cátira Bortolini Journal: PLoS One Date: 2015-09-18 Impact factor: 3.240